Advances in BCMA-CAR-T therapy of multiple myeloma and management after relapse
10.3969/j.issn.1006-5725.2025.07.001
- VernacularTitle:多发性骨髓瘤的B细胞成熟抗原靶向嵌合抗原受体T细胞治疗与复发后处理的研究进展
- Author:
Sijia YAN
1
;
Yi XIAO
1
Author Information
1. 华中科技大学同济医学院附属同济医院血液内科(湖北 武汉 430030)
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
BCMA-CAR-T;
relapse
- From:
The Journal of Practical Medicine
2025;41(7):929-935
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM)is a prevalent hematological malignancy.Despite the availability of various therapeutic agents,disease relapse remains inevitable.In recent years,B cell maturation antigen(BCMA)-targeted chimeric antigen receptor T(CAR-T)cell therapy has demonstrated remarkable success in treating relapsed/refractory(R/R)MM,offering new hope for RRMM patients.Currently,four types of BCMA-CAR-T products are available on the global market,and their application in RRMM is becoming increasingly widespread.However,RRMM patients who receive BCMA-CAR-T treatment still exhibit a high relapse rate.Research on maintenance therapy following BCMA-CAR-T treatment is currently limited,and multiple strategies exist for managing post-relapse RRMM after BCMA-CAR-T therapy.
